Final results from the Phase I study expansion cohort of the selective FGFR inhibitor Debio 1347 in patients with solid tumors harboring an FGFR gene fusion

Presented at ASCO 2020

James M. Cleary1, Gopa Iyer2, Do-Youn Oh3, Ingo K. Mellinghoff2, Lipika Goyal4, Matthew CH Ng5, Funda Meric-Bernstam6, Ignacio Matos7, Tsu-Yi Chao8, Rafik Ait Sarkouh9, Kira Cretegny9, Yassin Marzaoui9, Valerie Nicolas-Metral9, Anna Pokorska-Bocci9, Marie-Claude Roubaudi-Fraschini9, Anne Vaslin9, Claudio Zanna9, Angela Zubel9, Josep Tabernero7, Keith Flaherty4, David Hyman2

 

  1. Dana-Farber Cancer Institute, Boston, MA;
  2. Memorial Sloan-Kettering Cancer Center,
  3. Seoul National University Hospital, Seoul, Korea; New York, NY;
  4. Massachusetts General Hospital Cancer Center, Boston, MA;
  5. National Cancer Centre Singapore, Singapore;
  6. The University of Texas MD Anderson Cancer Center, Houston, TX;
  7. Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;
  8. Taipei Medical Hospital University, Taipei, Taiwan;
  9. Debiopharm International SA, Lausanne, Switzerland